ISPOR BOARD OF DIRECTORS ELECTION 2015

Published Mar 4, 2015
Dear Colleagues: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a member-driven organization led by a diverse Board of Directors and professional staff who work collaboratively to ensure the organization is strategically positioned and effectively serving its membership. As such, ISPOR members are encouraged to participate in the election for the 2015-2016 ISPOR Board of Directors and help shape the future of ISPOR. ABOUT THE CANDIDATES: The ISPOR Board of Directors consists of the Officers (President, President-Elect, Immediate Past President), and seven Directors. The Board term of office for the President is one year as President-Elect, one year as a President, and one year as a Past President. After an extensive review and deliberation of more than 60 nominees, the ISPOR Nominations Committee has recommended the following candidates for the 2015-16 Board election. (All ISPOR members are strongly encouraged to review the candidate backgrounds and vote in this election. To read the candidate's biographical summary and their ISPOR vision statement go to: Candidate biographical summaries & ISPOR vision statements.) President-elect Lou Garrison, PhD (USA) Maarten J. IJzerman, PhD (The Netherlands) Director (Position 1) Diego Rosselli, MD, MED, MHP (Colombia) Manuel Espinoza S., MD, MSc, PhD (Chile) Director (Position 2) Dana Goldman, PhD (USA) Todd Lee, PharmD, PhD (USA) Director (Position 3) Nancy Devlin, PhD (UK) Mitchell Higashi, PhD (USA) TO VOTE: Access the ballot clicking on the “VOTE NOW!” icon below. You will be directed to enter your ISPOR member email address and member ID. All ballots are verified and tabulated by an independent agency.

YOU MUST VOTE BY MAY 1, 2015

Sincerely, William H. Crown, PhD 2014-2015 Board of Directors Nominations Committee Chair & 2014-2015 Past-President Vote Now!

Related Stories

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.

ISPOR Champions Research Transparency With Launch of Open Science Badges

Aug 4, 2025

ISPOR introduced an initiative to recognize transparency in research for papers published in Value in Health, its preeminent HEOR journal.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×